The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
暂无分享,去创建一个
G. Redelman-Sidi | M. Postow | F. A. Romero | C. Kyi | M. del Castillo | E. Argüello | Gil Redelman-Sidi
[1] R. Sullivan,et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.
[2] M. Callahan,et al. Checkpoint Blockade for the Treatment of Advanced Melanoma. , 2016, Cancer treatment and research.
[3] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[4] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[5] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[6] J. Wolchok,et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] K. Papadakis,et al. Ipilimumab-induced colitis in patients with metastatic melanoma , 2015, Melanoma research.
[8] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[9] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[10] T. Harrer,et al. Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab. , 2015, Journal of immunotherapy.
[11] R. Krishnan,et al. Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control , 2015, Oncoimmunology.
[12] G. Linette,et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.
[13] M. Postow. Managing immune checkpoint-blocking antibody side effects. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[14] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[15] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[16] J. Wolchok,et al. Opportunistic infections in patients treated with immunotherapy for cancer , 2014, Journal of Immunotherapy for Cancer.
[17] A. Hauschild,et al. Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[19] S. Almo,et al. Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis , 2010, Proceedings of the National Academy of Sciences.
[20] J. Montoya,et al. Prevention and treatment of cancer-related infections. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.
[21] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] S. Way,et al. PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes1 , 2008, The Journal of Immunology.
[23] Lieping Chen,et al. Blockade of endogenous B7‐H1 suppresses antibacterial protection after primary Listeria monocytogenes infection , 2008, Immunology.
[24] K. Sepkowitz,et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.